Study Evaluating Venlafaxine ER in Patients With Panic Disorder

Back to Search
Print
Bookmark Trial

NCT00044772

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Panic Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1

- Have sufficient symptoms to require anxiolytic drug therapy

- Have a score ≥4 on the Clinical Global Impressions Scale (CGI) severity of illness item at screening and baseline

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine


- History or presence of any clinically important hepatic, renal, or other medical
disease that might compromise the study or be detrimental to the patient (eg,
clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
cell epithelioma], uncontrolled hypertension)


- Clinically important abnormality on screening physical examination, vital signs,
electrocardiogram (ECG), laboratory tests or urine drug screen

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Panic DisorderStudy Evaluating Venlafaxine ER in Adults With Panic Disorder
NCT00038896
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Panic DisorderA Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00677352
  1. Nagoya, Aichi
  2. Fukuoka-shi, Fukuoka
  3. Kitakyushu-shi, Fukuoka
  4. Kitakyusyu-shi, Fukuoka
  5. Sapporo-Shi, Hokkaido
  6. Sapporo, Hokkaido
  7. Higashiibaraki-gun, Ibaraki
  8. Fujisawa-city, Kanagawa
  9. Sagamihara-Shi, Kanagawa
  10. Yokohama-Shi, Kanagawa
  11. Yokohama, Kanagawa
  12. Kawaguchi-shi, Saitama
  13. Saitama city, Saitama
  14. Chiyoda-ku, Tokyo
  15. Kita-ku, Tokyo
  16. Minato-ku, Tokyo
  17. Musashino, Tokyo
  18. Nakano-Ku, Tokyo
  19. Nakanoku, Tokyo
  20. Setagaya-ku, Tokyo
  21. Shinjuku-ku, Tokyo
  22. Toshima-ku, Tokyo
  23. Nakano-ku, Yokohama
  24. Minato-ku,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Panic DisorderStudy Evaluating Venlafaxine ER in Patients With Panic Disorder
NCT00044772
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Panic DisorderA Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks
NCT00634790
  1. Little Rock, Alaska
  2. Phoenix, Arizona
  3. Scottsdale, Arizona
  4. Burbank, California
  5. Elcentro, California
  6. La Mesa, California
  7. Los Angeles, California
  8. Oceanside, California
  9. San Diego, California
  10. San Marcos, California
  11. Gainesville, Florida
  12. Hialeah, Florida
  13. Jacksonville, Florida
  14. North Miami, Florida
  15. St. Petersburg, Florida
  16. West Palm Beach, Florida
  17. Decatur, Georgia
  18. Boise, Idaho
  19. Schaumburg, Illinois
  20. Terre Haute, Indiana
  21. Overland Park, Kansas
  22. Lexington, Kentucky
  23. Owensboro, Kentucky
  24. New Orleans, Louisiana
  25. New Orleans, Louisiana
  26. Baltimore, Maryland
  27. Clinton Township, Michigan
  28. Saint Paul, Minnesota
  29. Omaha, Nebraska
  30. Las Vegas, Nevada
  31. Clementon, New Jersey
  32. Kenilworth, New Jersey
  33. Morristown, New Jersey
  34. Bismarck, North Dakota
  35. Cleveland, Ohio
  36. Lyndhurst, Ohio
  37. Eugene, Oregon
  38. Bala Cynwyd, Pennsylvania
  39. Hershey, Pennsylvania
  40. Media, Pennsylvania
  41. Columbia, South Carolina
  42. Selmer, Tennessee
  43. San Antonio, Texas
  44. Salt Lake City, Utah
  45. Midlothian, Virginia
  46. Richmond, Virginia
  47. Middleton, Wisconsin
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Venlafaxine ER in Patients With Panic Disorder
Official Title  ICMJE A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder
Brief Summary The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE Panic Disorder
Intervention  ICMJE Drug: Venlafaxine ER
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 13, 2009)		653
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE April 2003
Actual Primary Completion Date April 2003   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1
  • Have sufficient symptoms to require anxiolytic drug therapy
  • Have a score ?4 on the Clinical Global Impressions Scale (CGI) severity of illness item at screening and baseline

Exclusion Criteria:

  • Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine
  • History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal cell epithelioma], uncontrolled hypertension)
  • Clinically important abnormality on screening physical examination, vital signs, electrocardiogram (ECG), laboratory tests or urine drug screen
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00044772
Other Study ID Numbers  ICMJE 0600B5-399
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical Monitor, MDWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP